NCT02936492 - BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 24, 2016

Primary Completion Date

April 18, 2017

Study Completion Date

October 16, 2017

Conditions

Psoriasis

Interventions

DRUG

BAY1003803 0.01% lipophilic cream

Topical administration for 22 h per day

DRUG

BAY1003803 0.1% lipophilic cream

Topical administration for 22 h per day

DRUG

BAY1003803 0.01% ointment

Topical administration for 22 h per day

DRUG

BAY1003803 0.1% ointment

Topical administration for 22 h per day

DRUG

Lipophilic cream vehicle

Topical administration for 22 h per day

DRUG

Ointment vehicle

Topical administration for 22 h per day

DRUG

Clobetasol propionate

Topical administration for 22 h per day

Trial Locations (1)

Hamburg